封面
市场调查报告书
商品编码
1575000

研究性新药 CDMO 市场,按服务类型、按药物类型、按阶段、按最终用户、按国家和地区划分 - 2024-2032 年行业分析、市场规模、市场份额和预测

Investigational New Drug CDMO Market, By Service Type, By Drug Type, By Phase, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日期: | 出版商: AnalystView Market Insights | 英文 301 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年研究用新药CDMO市场规模为48.9032亿美元,2024年至2032年复合年增长率为6.90%。

研究性新药 CDMO 市场-市场动态

临床试验数量的增加加速了研究性新药 CDMO 市场的成长

临床试验数量的增加显着加速了研究性新药 (IND) CDMO 市场的成长。据世界卫生组织称,2022 年全球註册临床试验超过 40,000 项,反映出研究活动激增。美国 FDA 也报告 IND 申请量稳定成长,去年提交的申请数量达到近 5,000 份。这种上升是由生物技术的进步和新疗​​法的紧迫性所推动的,特别是在肿瘤学和罕见疾病等领域。 Catalent 和 Thermo Fisher Scientific 等主要参与者正在扩大其设施和能力,以满足不断增长的需求,为药物开发和製造提供量身定制的解决方案。此外,FDA 即时肿瘤学审查计画等措施旨在加快临床试验流程,进一步推动对高效 CDMO 服务的需求。随着製药公司越来越多地寻求与 CDMO 合作以简化其开发管道,市场有望持续扩张。

研究性新药 CDMO 市场 - 关键见解

根据我们的研究分析师分享的分析,预计全球市场在预测期内(2024-2032 年)每年将以 6.90% 左右的复合年增长率成长

根据服务类型细分,预计药品製造将在 2023 年显示最大的市场份额

根据药物类型细分,生物製剂是2023年的主导类型

按期数细分,2023年二期为主导类型

按地区划分,北美是 2023 年的主要收入来源

研究性新药 CDMO 市场-区隔分析:

全球研究性新药 CDMO 市场根据服务类型、药物类型、阶段、最终用户和区域进行细分。

根据服务类型,市场分为四类:原料药製造、药品製造、包装和标籤以及临床试验供应。药品製造因其在开发临床试验最终配方中的关键作用而处于领先地位。原料药製造紧随其后,临床试验供应和包装与标籤分别排名第三和第四。

根据药物类型,市场分为两类:小分子和生物製剂。生物製剂因其需求不断增加且製造製程复杂性而占据主导地位。小分子紧随其后,仍然占市场的很大一部分,特别是对于传统药品和仿製药而言。

研究性新药 CDMO 市场 - 地理洞察

研究性新药 (IND) CDMO 市场表现出显着的地理多样性,其中北美处于领先地位,特别是由于美国强大的製药格局。 FDA 报告 2022 年有超过 5,000 份 IND 申请,凸显了该地区活跃的临床试验环境。 Lonza 和 Catalent 等主要 CDMO 厂商已在该地区建立了广泛的设施,以满足不断增长的需求。欧洲紧追在后,德国和英国等国家大力投资生物製药研究;欧洲药品管理局支持多项简化临床试验审批的倡议,进一步鼓励 CDMO 合作伙伴关係。在亚太地区,在越来越多的临床试验和有利的监管环境的推动下,中国和印度等国家正在成为主要参与者; 2022 年,光是中国的临床试验註册量就成长了 35%。这种多样化的区域格局凸显了 IND CDMO 市场的全球成长潜力。

研究性新药 CDMO 市场-竞争格局:

研究性新药 (IND) CDMO 市场的竞争格局以各个地区的积极参与为标誌。北美是领先地区,是赛默飞世尔科技 (Thermo Fisher Scientific) 和康泰伦特 (Catalent) 等主要参与者的所在地,它们在处理 IND 项目方面利用先进技术和丰富经验。根据 FDA 报告, IND 申请数量到 2022 年将超过 5,000 份,这凸显了对这些服务的需求。欧洲也是一个强有力的竞争者,Lonza 和 Recipharm 等公司不断扩大业务以满足不断增长的市场需求;德国健全的监管架构和英国的临床试验法规对于吸引投资至关重要。在亚太地区,中国和印度生物製药中心的崛起引人注目,在旨在提高临床试验效率的政府倡议的支持下,药明康德等公司成为主要参与者。据报道,2022 年中国临床试验註册量将成长 35%,进一步凸显了这个快速发展的市场的竞争动态。

最新进展:

2023 年 10 月,Evaluate 推出了 CDMO Intelligence 解决方案,为合约开发和製造组织 (CDMO) 以及生物製药公司提供全面的市场洞察。该工具旨在优化快速成长的製药 CDMO 市场的策略,预计到 2028 年将大幅扩张。

2023年10月,Tanvex BioPharma推出Tanvex CDMO,为生物製剂提供全面的合约开发与製造服务。该中心位于圣地牙哥,拥有先进的设施,旨在协助生物製药公司将产品从研究性新药 (IND) 状态推进到上市准备阶段。

目录

第 1 章:研究性新药 CDMO 市场概述

  • 研究范围
  • 市场预估年份

第 2 章:执行摘要

  • 市场片段
    • 按服务类型分類的研究性新药 CDMO 市场片段
    • 按药物类型分類的研究性新药 CDMO 市场片段
    • 依阶段分類的研究性新药 CDMO 市场片段
    • 最终用户研究性新药 CDMO 市场片段
    • 按国家/地区分類的研究性新药 CDMO 市场片段
    • 按地区分類的研究性新药 CDMO 市场片段
  • 竞争洞察

第 3 章:研究性新药 CDMO 主要市场趋势

  • 研究性新药 CDMO 市场驱动因素
    • 市场驱动因素的影响分析
  • 研究性新药 CDMO 市场限制
    • 市场限制影响分析
  • 研究性新药 CDMO 市场机会
  • 研究性新药 CDMO 市场未来趋势

第 4 章:研究性新药 CDMO 产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章:研究性新药 CDMO 市场:COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章:研究性新药 CDMO 市场格局

  • 2023 年研究性新药 CDMO 市占率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章:研究性新药 CDMO 市场 - 按服务类型

  • 概述
    • 按服务类型分類的细分市场占有率分析
    • 原料药製造
    • 药品製造
    • 包装和标籤
    • 临床试验供应

第 8 章:研究性新药 CDMO 市场 - 按药物类型

  • 概述
    • 按药物类型分類的细分市场份额分析
    • 小分子
    • 生物製品

第 9 章:研究性新药 CDMO 市场 - 按阶段

  • 概述
    • 按阶段分類的细分市场占有率分析
    • 第一阶段
    • 第二阶段
    • 第三阶段

第 10 章:研究性新药 CDMO 市场 - 按最终用户

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 製药公司
    • 生物製药公司
    • 生技公司

第 11 章:研究性新药 CDMO 市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美研究性新药 CDMO 主要製造商
    • 北美市场规模和预测(按国家)
    • 北美市场规模和预测(按服务类型)
    • 北美市场规模和预测(按药物类型)
    • 北美市场规模和预测(按阶段)
    • 北美市场规模和预测(按最终用户)
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲研究性新药 CDMO 主要製造商
    • 欧洲市场规模和预测(按国家)
    • 欧洲市场规模和预测(按服务类型)
    • 欧洲市场规模和预测(按药物类型)
    • 欧洲市场规模与预测(按阶段)
    • 欧洲市场规模和预测(按最终用户)
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区在开发新药 CDMO 主要製造商
    • 亚太地区市场规模与预测(按国家)
    • 亚太地区市场规模与预测(按服务类型)
    • 亚太地区市场规模和预测(按药物类型)
    • 亚太地区市场规模及预测(按阶段)
    • 亚太地区市场规模和预测(按最终用户)
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲研究性新药 CDMO 主要製造商
    • 拉丁美洲市场规模与预测(按国家)
    • 拉丁美洲市场规模和预测(按服务类型)
    • 拉丁美洲市场规模与预测(按药物类型)
    • 拉丁美洲市场规模与预测(按阶段)
    • 拉丁美洲市场规模和预测(按最终用户)
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲在开发新药 CDMO 主要製造商
    • 中东和非洲市场规模及预测(按国家)
    • 中东和非洲市场规模及预测(按服务类型)
    • 中东和非洲市场规模及预测(按药物类型)
    • 中东和非洲市场规模及预测(按阶段)
    • 中东和非洲市场规模和预测(按最终用户)
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 12 章:主要供应商分析 - 研究性新药 CDMO 产业

  • 竞争仪表板
  • 公司简介
    • Almac Group Limited
    • Baxter BioPharma Solutions
    • Boehringer Ingelheim International GmbH
    • Cambrex Corporation
    • Catalent, Inc.
    • Charles River Laboratories International, Inc.
    • CordenPharma International GmbH
    • Fujifilm Diosynth Biotechnologies USA, Inc.
    • Jubilant Life Sciences Limited
    • Lonza Group AG
    • Patheon Inc. (Thermo Fisher Scientific)
    • Piramal Pharma Solutions
    • Recipharm AB
    • Samsung Biologics Co., Ltd.
    • Siegfried Holding AG
    • WuXi AppTec Co., Ltd.
    • Others

第 13 章:360 度分析师视角

第 14 章:附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV3987

REPORT HIGHLIGHT

Investigational New Drug CDMO Market size was valued at USD 4,890.32 Million in 2023, expanding at a CAGR of 6.90% from 2024 to 2032.

The Investigational New Drug (IND) Contract Development and Manufacturing Organization (CDMO) Market focuses on services that support pharmaceutical companies in developing and manufacturing new drug candidates for clinical trials. The increasing number of clinical trials and the demand for specialized manufacturing services are significant factors propelling market growth. Furthermore, the rising investment in biopharmaceutical research and development, with over $200 billion allocated globally in 2022, underscores the need for efficient CDMO partnerships. However, stringent regulatory requirements and the high cost of compliance can restrain market entry for new players. Opportunities are emerging in the biotechnology sector, where the demand for tailored manufacturing solutions is rising; for example, companies like Lonza and WuXi AppTec are expanding their capabilities to cater to the growing biologics market. Additionally, the shift towards personalized medicine is creating a need for more flexible and scalable manufacturing solutions, enhancing the overall potential for CDMOs in the IND space.

Investigational New Drug CDMO Market- Market Dynamics

Increasing Number of Clinical Trials Accelerates Growth of the Investigational New Drug CDMO Market

The increasing number of clinical trials is significantly accelerating the growth of the Investigational New Drug (IND) CDMO Market. According to the World Health Organization, over 40,000 clinical trials were registered globally in 2022, reflecting a surge in research activity. The U.S. FDA has also reported a steady rise in IND applications, reaching nearly 5,000 submissions in the last year. This uptick is driven by advancements in biotechnology and the urgency for new therapies, particularly in areas like oncology and rare diseases. Major players like Catalent and Thermo Fisher Scientific are expanding their facilities and capabilities to meet this rising demand, offering tailored solutions for drug development and manufacturing. Additionally, initiatives such as the FDA's Real-Time Oncology Review program aim to expedite the clinical trial process, further propelling the need for efficient CDMO services. As pharmaceutical companies increasingly seek partnerships with CDMOs to streamline their development pipelines, the market is poised for continued expansion.

Investigational New Drug CDMO Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.90% over the forecast period (2024-2032)

Based on Service Type segmentation, Drug Product Manufacturing was predicted to show maximum market share in the year 2023

Based on Drug Type segmentation, Biologics was the leading type in 2023

Based on Phase segmentation, Phase II was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Investigational New Drug CDMO Market- Segmentation Analysis:

The Global Investigational New Drug CDMO Market is segmented on the basis of Service Type, Drug Type, Phase, End-User, and Region.

The market is divided into four categories based on Service Type: Drug Substance Manufacturing, Drug Product Manufacturing, Packaging & Labeling, and Clinical Trial Supply. Drug Product Manufacturing leads due to its critical role in developing final formulations for clinical trials. Drug Substance Manufacturing follows closely, while Clinical Trial Supply and Packaging & Labeling rank third and fourth, respectively.

The market is divided into two categories based on Drug Type: Small Molecules and Biologics. Biologics take precedence due to their increasing demand and complexity in manufacturing processes. Small Molecules follow, still representing a significant portion of the market, particularly for traditional pharmaceuticals and generic drugs.

Investigational New Drug CDMO Market- Geographical Insights

The Investigational New Drug (IND) CDMO Market exhibits significant geographical diversity, with North America leading, particularly due to the United States' robust pharmaceutical landscape. The FDA reported over 5,000 IND applications in 2022, highlighting the region's active clinical trial environment. Major CDMO players like Lonza and Catalent have established extensive facilities in this region to cater to growing demand. Europe follows closely, with countries like Germany and the UK investing heavily in biopharmaceutical research; the European Medicines Agency supports numerous initiatives to streamline clinical trial approvals, further encouraging CDMO partnerships. In the Asia-Pacific region, countries like China and India are emerging as key players, driven by an increasing number of clinical trials and favorable regulatory environments; China alone saw a 35% rise in clinical trial registrations in 2022. The Indian government has also launched initiatives to enhance its clinical research capabilities, attracting foreign investments and strengthening its CDMO presence. This diverse regional landscape underscores the global potential for growth in the IND CDMO market.

Investigational New Drug CDMO Market- Competitive Landscape:

The Competitive Landscape of the Investigational New Drug (IND) CDMO Market is marked by active engagement across various regions. North America stands out as the leading region, home to major players like Thermo Fisher Scientific and Catalent, which leverage advanced technologies and extensive experience in handling IND projects. The FDA's reported increase in IND applications, exceeding 5,000 in 2022, underscores the demand for these services. Europe is also a strong contender, with companies like Lonza and Recipharm expanding their operations to meet the needs of a growing market; Germany's robust regulatory framework and the UK's Clinical Trial Regulations are pivotal in attracting investments. In the Asia-Pacific region, the rise of biopharmaceutical hubs in China and India is notable, with firms like WuXi AppTec emerging as key players, supported by governmental initiatives aimed at enhancing clinical trial efficiency. China's reported 35% increase in clinical trial registrations in 2022 further highlights the competitive dynamics in this fast-evolving market.

Recent Developments:

In October 2023, Evaluate launched its CDMO Intelligence solution, providing comprehensive market insights for contract development and manufacturing organizations (CDMOs) and biopharma firms. This tool aims to optimize strategies in the rapidly growing pharmaceutical CDMO market, projected to expand significantly through 2028.

In October 2023, Tanvex BioPharma launched Tanvex CDMO, providing comprehensive contract development and manufacturing services for biologics. Located in San Diego, it features advanced facilities and aims to assist biopharmaceutical companies in advancing products from investigational new drug (IND) status to market readiness.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INVESTIGATIONAL NEW DRUG CDMO MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Almac Group Limited
  • Baxter BioPharma Solutions
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • CordenPharma International GmbH
  • Fujifilm Diosynth Biotechnologies USA, Inc.
  • Jubilant Life Sciences Limited
  • Lonza Group AG
  • Patheon Inc. (Thermo Fisher Scientific)
  • Piramal Pharma Solutions
  • Recipharm AB
  • Samsung Biologics Co., Ltd.
  • Siegfried Holding AG
  • WuXi AppTec Co., Ltd.
  • Others

GLOBAL INVESTIGATIONAL NEW DRUG CDMO MARKET, BY SERVICE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Drug Substance Manufacturing
  • Drug Product Manufacturing
  • Packaging & Labeling
  • Clinical Trial Supply

GLOBAL INVESTIGATIONAL NEW DRUG CDMO MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Small Molecules
  • Biologics

GLOBAL INVESTIGATIONAL NEW DRUG CDMO MARKET, BY PHASE- MARKET ANALYSIS, 2019 - 2032

  • Phase I
  • Phase II
  • Phase III

GLOBAL INVESTIGATIONAL NEW DRUG CDMO MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Biotechnology Firms

GLOBAL INVESTIGATIONAL NEW DRUG CDMO MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Investigational New Drug CDMO Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Investigational New Drug CDMO Market Snippet by Service Type
    • 2.1.2. Investigational New Drug CDMO Market Snippet by Drug Type
    • 2.1.3. Investigational New Drug CDMO Market Snippet by Phase
    • 2.1.4. Investigational New Drug CDMO Market Snippet by End-User
    • 2.1.5. Investigational New Drug CDMO Market Snippet by Country
    • 2.1.6. Investigational New Drug CDMO Market Snippet by Region
  • 2.2. Competitive Insights

3. Investigational New Drug CDMO Key Market Trends

  • 3.1. Investigational New Drug CDMO Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Investigational New Drug CDMO Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Investigational New Drug CDMO Market Opportunities
  • 3.4. Investigational New Drug CDMO Market Future Trends

4. Investigational New Drug CDMO Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Investigational New Drug CDMO Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Investigational New Drug CDMO Market Landscape

  • 6.1. Investigational New Drug CDMO Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Investigational New Drug CDMO Market - By Service Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Service Type, 2023 & 2032 (%)
    • 7.1.2. Drug Substance Manufacturing
    • 7.1.3. Drug Product Manufacturing
    • 7.1.4. Packaging & Labeling
    • 7.1.5. Clinical Trial Supply

8. Investigational New Drug CDMO Market - By Drug Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
    • 8.1.2. Small Molecules
    • 8.1.3. Biologics

9. Investigational New Drug CDMO Market - By Phase

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Phase, 2023 & 2032 (%)
    • 9.1.2. Phase I
    • 9.1.3. Phase II
    • 9.1.4. Phase III

10. Investigational New Drug CDMO Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 10.1.2. Pharmaceutical Companies
    • 10.1.3. Biopharmaceutical Companies
    • 10.1.4. Biotechnology Firms

11. Investigational New Drug CDMO Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Investigational New Drug CDMO Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Investigational New Drug CDMO Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Investigational New Drug CDMO Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Investigational New Drug CDMO Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Investigational New Drug CDMO Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Investigational New Drug CDMO Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Almac Group Limited
    • 12.2.2. Baxter BioPharma Solutions
    • 12.2.3. Boehringer Ingelheim International GmbH
    • 12.2.4. Cambrex Corporation
    • 12.2.5. Catalent, Inc.
    • 12.2.6. Charles River Laboratories International, Inc.
    • 12.2.7. CordenPharma International GmbH
    • 12.2.8. Fujifilm Diosynth Biotechnologies USA, Inc.
    • 12.2.9. Jubilant Life Sciences Limited
    • 12.2.10. Lonza Group AG
    • 12.2.11. Patheon Inc. (Thermo Fisher Scientific)
    • 12.2.12. Piramal Pharma Solutions
    • 12.2.13. Recipharm AB
    • 12.2.14. Samsung Biologics Co., Ltd.
    • 12.2.15. Siegfried Holding AG
    • 12.2.16. WuXi AppTec Co., Ltd.
    • 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us